ArticleFrontiers in nutrition2026
Association of altered plasma long-chain fatty acids with migraine-related disability: a clinical cross-sectional study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The relationship between migraine and lipid metabolism, as well as its underlying mechanisms, remains poorly defined. In lipid metabolism, long-chain fatty acids (LCFAs) play a role in regulating cellular energy homeostasis and inflammation. Emerging evidence suggests a link between LCFAs and migraine pathophysiology. We investigated the association between altered plasma LCFAs and migraine-related disability. Methods: In this cross-sectional study, plasma samples and clinical data were collected from 118 individuals with migraine, comprising 79 with episodic migraine (EM) and 39 with chronic migraine (CM), and 118 matched healthy controls. Concentrations of 13 plasma LCFAs were quantified using targeted gas chromatography-mass spectrometry. Associations with migraine phenotype and clinical burden were assessed using regression and correlation analyses. Results: Plasma levels of palmitic acid (C16:0), stearic acid (C18:0), and arachidonic acid (C20:4 n-6) were significantly higher in migraine patients than in controls, whereas docosahexaenoic acid (C22:6 n-3) levels were significantly lower. Multivariate logistic regression identified C16:0, C18:0, and C20:4 n-6 as independent correlates of migraine (AUC = 0.912). Notably, higher levels of C16:0 and C20:4 n-6 were independently associated with with CM relative to EM (AUC = 0.762), and positively correlated with monthly headache days, acute medication use, and disability scores. Conclusion: Our study showed that increased concentrations of plasma LCFAs, specifically C16:0, C18:0, and C20:4 n-6, were independently associated with migraine. C16:0 and C20:4 n-6 were associated with the burden of migraine-related disability. These findings suggest a potential role for the regulation of lipid metabolism in the management and prevention of migraine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.